The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion--based formulation (AS02) and a formulation based on liposomes (AS01). In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01(E) or RTS,S/AS02(D), on a 0-1-2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02(D)/AS01(E)) of 0.88 (95% CI: 0.68-1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. RTS,S/AS01(E) proved similarly as well tolerated and immunogenic as RTS,S/AS02(D), completing an essential step in the age de-escalation process within the RTS,S clinical development plan. ClinicalTrials.gov. NCT00307021.
The malaria vaccine candidate antigen RTS , S includes parts of the pre - erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen . Two Adjuvant Systems are in development for this vaccine , an oil - in water emulsion -- based formulation ( AS02 ) and a formulation based on liposomes ( AS01 ) . In this Phase II , double - blind study ( NCT00307021 ) , 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS , S / AS01(E ) or RTS , S / AS02(D ) , on a 0 - 1 - 2 month vaccination schedule . The children were followed - up daily for six days after each vaccination and monthly for 14 months . Blood samples were collected at 4 time - points . Both vaccines were well tolerated . Safety parameters were distributed similarly between the two groups . Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti - CS GMT titers ( AS02(D)/AS01(E ) ) of 0.88 ( 95 % CI : 0.68 - 1.15 ) post - Dose 3 . After Doses 2 and 3 of experimental vaccines , anti - CS and anti - HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated . RTS , S / AS01(E ) proved similarly as well tolerated and immunogenic as RTS , S / AS02(D ) , completing an essential step in the age de - escalation process within the RTS , S clinical development plan . ClinicalTrials.gov . NCT00307021 .
RTS S AS01 vaccine was developed to prevent which disease?
RTS S AS01 vaccine was developed to prevent which disease ?
malaria
malaria